Gufic Biosciences Limited (Gufic) has received regulatory approval from the Therapeutic Group Administration (TGA) in Australia and the National Health Surveillance Agency (ANVISA) in Brazil for Parecoxib Sodium 40mg Lyophilized Powder for Injection. This selective COX-2 inhibitor is approved for the short-term treatment of acute pain and post-operative pain in adult patients. The approval marks […]
Gufic Biosciences has received approval from the National Medical Products Administration (NMPA) in China for its product, Prilocaine (API), an amide-type local anesthetic. The approval will aid in the commercialization of Prilocaine in China, opening up new opportunities in the Chinese market for Gufic. Prilocaine, which shares a similar clinical profile to lidocaine, is used […]
Gufic Biosciences has secured approval from the Drugs Controller General of India (DCGI) for Thymosin Alpha-1 (Immunocin α) as an add-on therapy for the treatment of moderate-to-severe Covid-19 patients needing ventilator support (NIV and mechanical ventilation). Immunocin α, which is an immuno-modulator drug, considerably cut down the risk of death in phase 3 clinical trial […]